BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37819535)

  • 21. The PD-1/B7-H1 pathway modulates the natural killer cells versus mouse glioma stem cells.
    Huang BY; Zhan YP; Zong WJ; Yu CJ; Li JF; Qu YM; Han S
    PLoS One; 2015; 10(8):e0134715. PubMed ID: 26266810
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells.
    Rao G; Latha K; Ott M; Sabbagh A; Marisetty A; Ling X; Zamler D; Doucette TA; Yang Y; Kong LY; Wei J; Fuller GN; Benavides F; Sonabend AM; Long J; Li S; Curran M; Heimberger AB
    Clin Cancer Res; 2020 Sep; 26(17):4699-4712. PubMed ID: 32554515
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Shevtsov M; Pitkin E; Ischenko A; Stangl S; Khachatryan W; Galibin O; Edmond S; Lobinger D; Multhoff G
    Front Immunol; 2019; 10():454. PubMed ID: 30967859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glioma-associated mesenchymal stem cells-mediated PD-L1 expression is attenuated by Ad5-Ki67/IL-15 in GBM treatment.
    Zhang Q; Zhang J; Wang P; Zhu G; Jin G; Liu F
    Stem Cell Res Ther; 2022 Jun; 13(1):284. PubMed ID: 35765095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oleandrin, a cardiac glycoside, induces immunogenic cell death via the PERK/elF2α/ATF4/CHOP pathway in breast cancer.
    Li X; Zheng J; Chen S; Meng FD; Ning J; Sun SL
    Cell Death Dis; 2021 Mar; 12(4):314. PubMed ID: 33762577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 27. Combination checkpoint therapy with anti-PD-1 and anti-BTLA results in a synergistic therapeutic effect against murine glioblastoma.
    Choi J; Medikonda R; Saleh L; Kim T; Pant A; Srivastava S; Kim YH; Jackson C; Tong L; Routkevitch D; Jackson C; Mathios D; Zhao T; Cho H; Brem H; Lim M
    Oncoimmunology; 2021; 10(1):1956142. PubMed ID: 34484870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma.
    Tong L; Li J; Li Q; Wang X; Medikonda R; Zhao T; Li T; Ma H; Yi L; Liu P; Xie Y; Choi J; Yu S; Lin Y; Dong J; Huang Q; Jin X; Lim M; Yang X
    Theranostics; 2020; 10(13):5943-5956. PubMed ID: 32483429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenic cell death induced by a new photodynamic therapy based on photosens and photodithazine.
    Turubanova VD; Balalaeva IV; Mishchenko TA; Catanzaro E; Alzeibak R; Peskova NN; Efimova I; Bachert C; Mitroshina EV; Krysko O; Vedunova MV; Krysko DV
    J Immunother Cancer; 2019 Dec; 7(1):350. PubMed ID: 31842994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Connective tissue growth factor as an unfavorable prognostic marker promotes the proliferation, migration, and invasion of gliomas.
    Song ZB; Yang HP; Xu AQ; Zhan ZM; Song Y; Li ZY
    Chin Med J (Engl); 2020 Mar; 133(6):670-678. PubMed ID: 32197031
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dendritic cell-mediated delivery of doxorubicin-polyglycerol-nanodiamond composites elicits enhanced anti-cancer immune response in glioblastoma.
    Li TF; Li K; Zhang Q; Wang C; Yue Y; Chen Z; Yuan SJ; Liu X; Wen Y; Han M; Komatsu N; Xu YH; Zhao L; Chen X
    Biomaterials; 2018 Oct; 181():35-52. PubMed ID: 30071380
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Platycodin D suppresses proliferation, migration, and invasion of human glioblastoma cells through regulation of Skp2.
    Li H; Ouyang J; Liu R
    Eur J Pharmacol; 2023 Jun; 948():175697. PubMed ID: 36997048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment.
    Wu A; Maxwell R; Xia Y; Cardarelli P; Oyasu M; Belcaid Z; Kim E; Hung A; Luksik AS; Garzon-Muvdi T; Jackson CM; Mathios D; Theodros D; Cogswell J; Brem H; Pardoll DM; Lim M
    J Neurooncol; 2019 Jun; 143(2):241-249. PubMed ID: 31025274
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Xihuang Pill-destabilized CD133/EGFR/Akt/mTOR cascade reduces stemness enrichment of glioblastoma via the down-regulation of SOX2.
    Xu L; Duan H; Zou Y; Wang J; Liu H; Wang W; Zhu X; Chen J; Zhu C; Yin Z; Zhao X; Wang Q
    Phytomedicine; 2023 Jun; 114():154764. PubMed ID: 36963368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase-Transformation Nanoparticle-Mediated Sonodynamic Therapy: An Effective Modality to Enhance Anti-Tumor Immune Response by Inducing Immunogenic Cell Death in Breast Cancer.
    Si Y; Yue J; Liu Z; Li M; Du F; Wang X; Dai Z; Hu N; Ju J; Gao S; Wang X; Yuan P
    Int J Nanomedicine; 2021; 16():1913-1926. PubMed ID: 33707946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth.
    Lamano JB; Lamano JB; Li YD; DiDomenico JD; Choy W; Veliceasa D; Oyon DE; Fakurnejad S; Ampie L; Kesavabhotla K; Kaur R; Kaur G; Biyashev D; Unruh DJ; Horbinski CM; James CD; Parsa AT; Bloch O
    Clin Cancer Res; 2019 Jun; 25(12):3643-3657. PubMed ID: 30824583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.
    Zeng J; See AP; Phallen J; Jackson CM; Belcaid Z; Ruzevick J; Durham N; Meyer C; Harris TJ; Albesiano E; Pradilla G; Ford E; Wong J; Hammers HJ; Mathios D; Tyler B; Brem H; Tran PT; Pardoll D; Drake CG; Lim M
    Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):343-9. PubMed ID: 23462419
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines.
    Rubner Y; Muth C; Strnad A; Derer A; Sieber R; Buslei R; Frey B; Fietkau R; Gaipl US
    Radiat Oncol; 2014 Mar; 9(1):89. PubMed ID: 24678590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
    Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
    J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cyclovirobuxine D inhibits cell proliferation and migration and induces apoptosis in human glioblastoma multiforme and low‑grade glioma.
    Zhou L; Tang H; Wang F; Ou S; Wu T; Fang Y; Xu J; Guo K
    Oncol Rep; 2020 Mar; 43(3):807-816. PubMed ID: 32020219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.